CONFLICT OF INTEREST
All authors report no conflict of interests.
To the Editor,
On December 2020, the U.S. Food and Drug Administration issued the first emergency use authorization for the Pfizer‐BioNtTech vaccine (PBV) for the prevention of coronavirus disease 2019 (COVID‐19) in individuals 16 years of age and older (https://www.fda.gov/emergency‐preparedness‐and‐response/coronavirus‐disease‐2019‐covid‐19/pfizer‐biontech‐covid‐19‐vaccine). Subsequently, reports of immediate allergic reactions (4.7 cases per 1 million injections) were captured in the Vaccine Adverse Event Reporting System and sorted according to the Brighton Collaboration case definition anaphylaxis criteria. 1 While polyethylene glycol (PEG) is the suspected culprit excipient, the mechanism of these immediate reactions, especially when occurring after the first vaccine, is unclear. 2 , 3 Although cases where a 2nd vaccine dose was administered safely following immediate reactions to the first dose were reported, 4 currently, the Center of Disease Control recommends that patients who experienced an immediate allergic reaction of any severity after the first dose of the vaccine should avoid the second dose (https://www.cdc.gov/coronavirus/2019‐ncov/vaccines/safety/allergic‐reaction.html). Routine administration of the PBV in Israel began in January 2021. Here, we report the results of evaluation of patients experiencing immediate reactions to the 1st dose and the results of administration of a 2nd dose.
An allergist interviewed patients with suspected immediate reactions (within 4 h of PBV administration). Anaphylaxis was classified in accordance with the Brighton collaboration case definition for anaphylaxis. 5 Skin prick tests (SPT) with the PBV and with Methylprednisolone solution for injection containing PEG 3350 (1:100, 1:10, and undiluted), and intradermal (ID) tests with Methylprednisolone (1:100) were performed, as recommended. 6 A second vaccine dose was administered under observation. Publication was approved by each institutional review board committee.
Eighteen patients with a mean age of 54.3 years (range, 23–75) were included (Table 1). Mean time interval from PBV receipt to symptoms onset was 28.9 min (range, 5–60 min). Eleven (63.2%) patients had non‐anaphylactic immediate reactions, and seven patients (36.8%) experienced anaphylaxis. None had hypotension or syncope. Fifteen patients underwent SPT to PBV and sixteen underwent SPT and ID tests to Methylprednisolone, which were all negative (Table 2). All patients received a second PBV dose, 12 following pretreatment with antihistamines. Four individuals had an immediate reaction after the second PBV dose, which was milder than the index reaction, and none required emergency room treatment or adrenaline.
TABLE 1.
Demographics and reactions following the 1st dose of the Pfizer‐BioNtTech COVID‐19 vaccine
| Pt. | Age | Gender | Atopic disease | Drugs/RCM/Food allergy | Signs and symptoms | Reaction onset (m) | Treatment setting | Drug treatment |
|---|---|---|---|---|---|---|---|---|
| 1 | 75 | F | Dyspnea | 15 | Primary physician | AH | ||
| 2 | 59 | M | Generalized rash, weakness | 60 | ER | AH, steroids | ||
| 3 | 57 | F | Diffuse pruritic rash | 60 | ER | AH, steroids | ||
| 4 | 23 | F | Diffuse pruritic rash | 30 | Emergency center | AH, steroids | ||
| 5 | 70 | F | Diffuse rash | 30 | Primary physician | AH | ||
| 6 | 27 | F | Diffuse pruritic rash | 15 | ER | AH | ||
| 7 | 68 | F | Generalized urticaria | 30 | ER | steroids | ||
| 8 | 52 | F | AR | Congestion, swelling of rt side of face a | 20 | ER | AH, steroids | |
| 9 | 53 | M | Penicillin | Hoarseness, urticaria a | 30 | ER | AH, steroids | |
| 10 | 47 | F | facial swelling | 10 | Vaccination center | AH | ||
| 11 | 39 | F | sensation of throat closure, tongue swelling a | 5 | ER | AH, steroids | ||
| 12 | 73 | F | Penicillin, ciprofloxacin | Tongue and lips swelling, generalized rash a | 30 | Vaccination center | AH, steroids | |
| 13 | 71 | F | NSAID, Lipitor, Morphine | Swollen face and redness | 60 | Vaccination center | AH | |
| 14 | 51 | M | Asthma, AR | RCM | Diffuse rash | 15 | Vaccination center | AH,steroids |
| 15 | 61 | M | AR | Pruritus, sensation of throat closure a | 10 | Vaccination center | AH | |
| 16 | 60 | F | AR | Sterocort | Swollen face and redness | 40 | Vaccination center | AH, steroids |
| 17 | 33 | F | Latex | Diffuse pruritic rash, vomiting a | 30 | ER | AH, steroids | |
| 18 | 58 | F | Asthma | Cough, Diffuse rash a | 30 | ER | AH, steroids |
Abbreviations: AH, anti histamines; AR, allergic rhinitis; ER, emergency room; RCM, radiocontrast media.
Patients meeting a definition of anaphylaxis (Patient 12, Brighton level 1; Patients 8, 9, 11, 18, Brighton level 2, patients 15, 17 Brighton level 3).
TABLE 2.
Results of allergic evaluation and of administration of the second BioNtTech COVID‐19 vaccine dose
| Pt. | Vaccine SPT | PEG SPT/ID | Premedication before second dose | Reaction to second dose |
|---|---|---|---|---|
| 1 | Negative | Negative | No | No |
| 2 | Negative | Negative | No | No |
| 3 | Negative | Negative | No | No |
| 4 | Negative | Negative | No | No |
| 5 | Negative | Negative | No | No |
| 6 | ND | ND | No | No |
| 7 | Negative | Negative | AH | No |
| 8 | Negative | Negative | AH | Tongue swelling |
| 9 | Negative | Negative | AH | No |
| 10 | Negative | Negative | AH | No |
| 11 | ND | Negative | AH | Itching in the throat |
| 12 | Negative | Negative | AH | No |
| 13 | ND | ND | AH | No |
| 14 | Negative | Negative | AH | No |
| 15 | Negative | Negative | AH | No |
| 16 | Negative | Negative | AH | Swelling on the right side of the face |
| 17 | Negative | Negative | AH | No |
| 18 | Negative | Negative | AH | Persistent cough, facial redness |
COVID‐19 has caused more than 3 million deaths and a worldwide economic crisis since its emergence in December 2019. 7 The newly developed vaccines provide hope for ending the pandemic. However, allergic reactions to the vaccine might impair this effort not only by preventing the administration of a 2nd dose but also by reducing compliance with the 1st dose. Israel was among the first countries to implement a vaccination program on a population level, enabling investigation of allergic reactions. The current report presents a cohort of individuals who had immediate reactions to the first PBV dose and received a second dose with only minor side effects. The presented data raise a question regarding the mechanisms provoking these immediate reactions, especially given that most patients received the second dose with mild or no symptoms. Concerns were raised regarding the role of PEG allergy in immediate reactions. Although current diagnostic methods for PEG allergy are not optimal, 8 our workup expands reports by others 4 and questions the role of IgE‐sensitization to the vaccine or to PEG as their cause. Finally, and most importantly, we demonstrated the safety of a second dose of PBV in patients with mild‐moderate immediate reactions to the first dose. While a few patients experienced adverse reactions to the 2nd dose, those were mild and do not justify its avoidance. This study is limited because most patients had mild to moderate reactions to the first PBV dose reported. Still, those with a severe reaction received the second dose as well.
In conclusion, we suggest that routine SPT to the vaccine or to PEG, in patients with mild‐moderate immediate reactions to the first dose of the PBV, need not be performed. A second dose of the vaccine should be considered in these patients, under appropriate medical supervision.
Ronit Confino‐Cohen and Arnon Elizur contribute equally to the study.
REFERENCES
- 1. Shimabukuro T, Nair N. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer‐BioNTech COVID‐19 vaccine. JAMA. 2021;325(8):780‐781. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Castells MC, Phillips EJ. Maintaining safety with SARS‐CoV‐2 vaccines. N Engl J Med. 2021;384(7):643‐649. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Banerji A, Wolfson AR, Wickner PG, et al. mRNA vaccines to prevent COVID‐19 disease and reported allergic reactions: current evidence and suggested approach. J Allergy Clin Immunol Pract. 2021;15:S2213‐2198(21)00439‐6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Krantz MS, Bruusgaard‐Mouritsen MA, Koo G, Phillips EJ, Stone CA Jr, Garvey LH. Anaphylaxis to the first dose of mRNA SARS‐CoV‐2 vaccines: don't give up on the second dose! Allergy. 2021;76(9):2916‐2920. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Rüggeberg JU, Gold MS, Bayas JM, et al. Brighton collaboration anaphylaxis working group. Vaccine. 2007;25(31):5675‐5684. [DOI] [PubMed] [Google Scholar]
- 6. Banerji A, et al. mRNA vaccines to prevent COVID 19 disease and reported allergic reactions: current evidence and suggested approach. J Allergy Clin Immunol Pract. 2021;9(4):1423‐1437. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Rossen LM, Branum AM, Ahmad FB, Sutton P, Anderson RN. Excess deaths associated with COVID‐19, by age and race and ethnicity—United States, January 26–October 3, 2020. MMWR: Morb Mortal Wkly Rep. 2020;69(42):1522‐1527. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Troelnikov A, Perkins G, Yuson C, et al. Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in patients with PEG allergy. J Allergy Clin Immunol. 2021;148(1):91‐95. [DOI] [PubMed] [Google Scholar]